Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia
| Status: | Completed |
|---|---|
| Conditions: | Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 3/16/2019 |
| Start Date: | March 10, 2016 |
| End Date: | December 20, 2017 |
Four methods are routinely used to monitor CO2 in patients. End tidal CO2 (EtCO2) is
monitored through the endotracheal tube during general anesthesia. CO2 is also monitored in
other healthcare settings transcutaneously (TCO2), via finger stick capillary CO2 (CapCO2),
and arterial blood gas (ABG). The purpose of this study is to perform all four measurements
simultaneously during general anesthesia to identify which measure provides the most accurate
data with the least amount of patient risk.
monitored through the endotracheal tube during general anesthesia. CO2 is also monitored in
other healthcare settings transcutaneously (TCO2), via finger stick capillary CO2 (CapCO2),
and arterial blood gas (ABG). The purpose of this study is to perform all four measurements
simultaneously during general anesthesia to identify which measure provides the most accurate
data with the least amount of patient risk.
Inclusion Criteria:
- Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value ≥ 60
mEq/L) and/or genotype with two identifiable mutations consistent with CF, accompanied
by one or more clinical features consistent with the CF phenotype)
- Hemodynamically stable undergoing general anesthesia for a scheduled procedure
Exclusion Criteria:
- Patients not diagnosed with CF
- CF patients undergoing anesthesia for emergency procedures
We found this trial at
1
site
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
Click here to add this to my saved trials
